![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Demeetra AgBio
Main focus: Therapeutic cannabis
Company stage: IND filing
Diseases: Undisclosed
Genome editing tool: Cas-CLOVER
Funding stage: Private
Location: Lexington, KY, USA
Website: https://demeetra.com/
Partners: Poseida Therapeutics, Sanofi
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_demeetra_f1996322f3_5e7b7b1597.png)
Demeetra Agbio is a privately held agricultural and therapeutic gene-editing company. Based in Kentrucky, US, the company utilises its proprietary Cas-CLOVER platform to genetically modify plants for pharmaceutical use. The Cas-CLOVER system uses two guide RNAs (gRNAs) rather than the conventional single gRNA used in CRISPR-Cas9 editing. Demeetra Agbio's components are licensed to several companies including Sanofi and Poseida Therapeutics.